Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590546 | 0.84 | DHFR (0.54) | TP53HSD17B10DHFRKMT2AKDM4E | |
| SCHEMBL8592527 | 0.83 | MAPT (0.47) | TP53HSD17B10DHFRKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL8590325 | 0.74 | KDM4E (0.32) | TP53HSD17B10DHFRKMT2AKDM4E | |
| Iodide SCHEMBL8591609 | 0.74 | KDM4E (0.32) | TP53HSD17B10DHFRKMT2AKDM4E | |
| SCHEMBL7081921 | 0.72 | HSP90AA1 (0.36) | TP53DHFRKMT2AKDM4EMEN1 | |
| SCHEMBL669554 | 0.66 | CA5A (0.67) | KMT2ASMN1; SMN2CA5AMEN1NPC1 | |
| SCHEMBL30595010 | 0.66 | BRD4 (0.54) | TP53HSD17B10KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL12311026 | 0.65 | CA5A (0.48) | TP53KDM4ESMN1; SMN2CA5ATDP1 | |
| SCHEMBL15835579 | 0.65 | DHODH (0.48) | TP53HSD17B10KDM4ESMN1; SMN2CA5A | |
| SCHEMBL1976289 | 0.65 | CA5A (0.52) | KMT2AKDM4ECA5ATDP1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649797-B2 | Contacting protein with a compound that is capable of stable reversible binding with basic amino acid residues of nuclear localization signal of protein for inactivating a nuclear localization signal of a protein | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-18 | — | — | US | disclosed |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2002-06-20 | — | — | US | disclosed |
| EP-0865434-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-09-23 | — | — | EP | disclosed |
| EP-0865434-A4 | — | — | 1998-09-23 | — | — | EP | disclosed |
| WO-1996020932-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | TP53 822/4885HSD17B10 2601/4885DHFR 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.